BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20185823)

  • 21. Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer.
    Fujikane T; Nishikawa N; Toyota M; Suzuki H; Nojima M; Maruyama R; Ashida M; Ohe-Toyota M; Kai M; Nishidate T; Sasaki Y; Ohmura T; Hirata K; Tokino T
    Breast Cancer Res Treat; 2010 Aug; 122(3):699-710. PubMed ID: 19859801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers.
    Biswas DK; Dai SC; Cruz A; Weiser B; Graner E; Pardee AB
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10386-91. PubMed ID: 11517301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5-Aza-2'-deoxycytidine induces a greater inflammatory change, at the molecular levels, in normoxic than hypoxic tumor microenvironment.
    Salviano Soares de Amorim Í; Rodrigues JA; Nicolau P; König S; Panis C; de Souza da Fonseca A; Mencalha AL
    Mol Biol Rep; 2021 Feb; 48(2):1161-1169. PubMed ID: 33547534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Essential function for PDLIM2 in cell polarization in three-dimensional cultures by feedback regulation of the β1-integrin-RhoA signaling axis.
    Deevi RK; Cox OT; O'Connor R
    Neoplasia; 2014 May; 16(5):422-31. PubMed ID: 24863845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
    Rubinstein JC; Tran N; Ma S; Halaban R; Krauthammer M
    BMC Med Genomics; 2010 Feb; 3():4. PubMed ID: 20144234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth.
    Nakshatri H; Bhat-Nakshatri P; Martin DA; Goulet RJ; Sledge GW
    Mol Cell Biol; 1997 Jul; 17(7):3629-39. PubMed ID: 9199297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer.
    Cox OT; Edmunds SJ; Simon-Keller K; Li B; Moran B; Buckley NE; Bustamante-Garrido M; Healy N; O'Flanagan CH; Gallagher WM; Kennedy RD; Bernards R; Caldas C; Chin SF; Marx A; O'Connor R
    Cancer Res; 2019 May; 79(10):2619-2633. PubMed ID: 30885980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine.
    David GL; Yegnasubramanian S; Kumar A; Marchi VL; De Marzo AM; Lin X; Nelson WG
    Cancer Biol Ther; 2004 Jun; 3(6):540-8. PubMed ID: 15034303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer.
    Singh S; Shi Q; Bailey ST; Palczewski MJ; Pardee AB; Iglehart JD; Biswas DK
    Mol Cancer Ther; 2007 Jul; 6(7):1973-82. PubMed ID: 17620428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of NF-κB activation by PDLIM2 restrains hepatic lipogenesis and inflammation in high fat diet induced mice.
    Hao YR; Tang FJ; Zhang X; Wang H
    Biochem Biophys Res Commun; 2018 Sep; 503(2):564-571. PubMed ID: 29852170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of transforming growth factor-beta receptor type II expression in estrogen receptor-positive breast cancer cells through SP1 activation by 5-aza-2'-deoxycytidine.
    Ammanamanchi S; Kim SJ; Sun LZ; Brattain MG
    J Biol Chem; 1998 Jun; 273(26):16527-34. PubMed ID: 9632722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
    Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
    Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic regulation of MDR1 gene in breast cancer: CpG methylation status dominates the stable maintenance of a silent gene.
    Sharma D; Vertino PM
    Cancer Biol Ther; 2004 Jun; 3(6):549-50. PubMed ID: 15254426
    [No Abstract]   [Full Text] [Related]  

  • 34. Methylation-mediated regulation of the glutathione S-transferase P1 gene in human breast cancer cells.
    Jhaveri MS; Morrow CS
    Gene; 1998 Mar; 210(1):1-7. PubMed ID: 9524203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic effects of combined DNA methyltransferase inhibition and MBD2 depletion on breast cancer cells; MBD2 depletion blocks 5-aza-2'-deoxycytidine-triggered invasiveness.
    Cheishvili D; Chik F; Li CC; Bhattacharya B; Suderman M; Arakelian A; Hallett M; Rabbani SA; Szyf M
    Carcinogenesis; 2014 Nov; 35(11):2436-46. PubMed ID: 25178277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells.
    Keen JC; Garrett-Mayer E; Pettit C; Mack KM; Manning J; Herman JG; Davidson NE
    Cancer Biol Ther; 2004 Dec; 3(12):1304-12. PubMed ID: 15662126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic control of NF-κB-dependent FAS gene transcription during progression of myelodysplastic syndromes.
    Ettou S; Humbrecht C; Benet B; Billot K; d'Allard D; Mariot V; Goodhardt M; Kosmider O; Mayeux P; Solary E; Fontenay M
    Mol Cancer Res; 2013 Jul; 11(7):724-35. PubMed ID: 23604035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure.
    Woodfield GW; Hitchler MJ; Chen Y; Domann FE; Weigel RJ
    Clin Cancer Res; 2009 Jun; 15(11):3672-9. PubMed ID: 19458056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NF-κB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT.
    Nakshatri H; Appaiah HN; Anjanappa M; Gilley D; Tanaka H; Badve S; Crooks PA; Mathews W; Sweeney C; Bhat-Nakshatri P
    Cell Death Dis; 2015 Jan; 6(1):e1608. PubMed ID: 25611383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exosome-mediated miR-222 transferring: An insight into NF-κB-mediated breast cancer metastasis.
    Ding J; Xu Z; Zhang Y; Tan C; Hu W; Wang M; Xu Y; Tang J
    Exp Cell Res; 2018 Aug; 369(1):129-138. PubMed ID: 29778754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.